

SYNAPTICS INC
Form 10-Q
May 03, 2013
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 30, 2013

Commission file number 000-49602

SYNAPTICS INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of

77-0118518
(I.R.S. Employer

Edgar Filing: SYNAPTICS INC - Form 10-Q

incorporation or organization)

3120 Scott Blvd.

Identification No.)

Santa Clara, California 95054

(Address of principal executive offices) (Zip code)

(408) 454-5100

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Number of shares of Common Stock outstanding at April 26, 2013: 32,484,761

Table of Contents

SYNAPTICS INCORPORATED
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2013
TABLE OF CONTENTS

| | Page |
|----------------------------------------------------------------------------------------------------------------------|-------------|
| <u>Part I. Financial Information</u> | |
| <u>Item 1. Condensed Financial Statements (Unaudited):</u> | |
| <u>Condensed Consolidated Balance Sheets March 31, 2013 and June 30, 2012</u> | 3 |
| <u>Condensed Consolidated Statements of Income Three and Nine Months Ended March 31, 2013 and 2012</u> | 4 |
| <u>Condensed Consolidated Statements of Comprehensive Income Three and Nine Months Ended March 31, 2013 and 2012</u> | 5 |
| <u>Condensed Consolidated Statements of Cash Flows Nine Months Ended March 31, 2013 and 2012</u> | 6 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 7 |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 17 |
| <u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u> | 23 |
| <u>Item 4. Controls and Procedures</u> | 23 |
| <u>Part II. Other Information</u> | |
| <u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u> | 24 |
| <u>Item 6. Exhibits</u> | 25 |
| <u>Signatures</u> | 26 |

Table of Contents**PART I FINANCIAL INFORMATION**

ITEM 1. CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
SYNAPTICS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(unaudited)

| | March 31, 2013 | June 30, 2012 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------------|
| ASSETS | | |
| Current Assets: | | |
| Cash and cash equivalents | \$ 315,513 | \$ 305,005 |
| Accounts receivable, net of allowances of \$567 at March 31, 2013 and June 30, 2012 | 106,700 | 104,140 |
| Inventories | 43,911 | 31,667 |
| Prepaid expenses and other current assets | 4,873 | 5,365 |
| Total current assets | 470,997 | 446,177 |
| Property and equipment at cost, net of accumulated depreciation of \$38,926 and \$33,129 at March 31, 2013 and June 30, 2012, respectively | 52,686 | 24,903 |
| Goodwill | 20,695 | 18,995 |
| Purchased intangibles | 13,372 | 12,800 |
| Non-current investments | 15,801 | 15,321 |
| Other assets | 27,939 | 23,309 |
| | \$ 601,490 | \$ 541,505 |
| LIABILITIES AND STOCKHOLDERS EQUITY | | |
| Current Liabilities: | | |
| Accounts payable | \$ 64,795 | \$ 55,220 |
| Accrued compensation | 16,321 | 12,642 |
| Income taxes payable | 11,512 | 11,221 |
| Other accrued liabilities | 34,365 | 26,515 |
| Total current liabilities | 126,993 | 105,598 |
| Notes payable | 2,305 | 2,305 |
| Other liabilities | 17,518 | 36,812 |
| Stockholders' Equity: | | |
| Common stock: | | |
| \$0.001 par value; 120,000,000 shares authorized, 49,446,155 and 48,680,348 shares issued, and 32,421,623 and 32,896,256 shares outstanding, at March 31, 2013 and June 30, 2012, respectively | 49 | 49 |
| Additional paid-in capital | 504,440 | 471,569 |
| Treasury stock: 17,024,532 and 15,784,092 common treasury shares at March 31, 2013 and June 30, 2012, respectively, at cost | (445,165) | (413,885) |
| Accumulated other comprehensive income | 4,678 | 1,998 |
| Retained earnings | 390,672 | 337,059 |
| Total stockholders' equity | 454,674 | 396,790 |

\$ 601,490 \$ 541,505

See notes to condensed consolidated financial statements (unaudited).

Table of Contents**SYNAPTICS INCORPORATED AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

(in thousands, except per share data)

(unaudited)

| | Three Months Ended March 31, | | Nine Months Ended March 31, | |
|----------------------------------------------------|---------------------------------|------------|--------------------------------|------------|
| | 2013 | 2012 | 2013 | 2012 |
| Net revenue | \$ 163,324 | \$ 131,705 | \$ 433,405 | \$ 410,621 |
| Cost of revenue | 82,241 | 69,525 | 222,722 | 218,458 |
| Gross margin | 81,083 | 62,180 | 210,683 | 192,163 |
| Operating expenses: | | | | |
| Research and development | 36,740 | 29,415 | 103,799 | 87,478 |
| Selling, general, and administrative | 20,183 | 18,031 | 58,099 | 52,461 |
| Acquired intangibles amortization | 262 | | 763 | |
| Change in contingent consideration | 237 | | 1,100 | |
| Total operating expenses | 57,422 | 47,446 | 163,761 | 139,939 |
| Operating income | 23,661 | 14,734 | 46,922 | 52,224 |
| Interest income | 197 | 231 | 640 | 682 |
| Interest expense | (4) | (4) | (13) | (13) |
| Impairment recovery on investments, net | | 46 | | 59 |
| Income before (benefit)/provision for income taxes | 23,854 | 15,007 | 47,549 | 52,952 |
| (Benefit)/provision for income taxes | (12,592) | 3,561 | (6,064) | 11,108 |
| Net income | \$ 36,446 | \$ 11,446 | \$ 53,613 | \$ 41,844 |
| Net income per share: | | | | |
| Basic | \$ 1.13 | \$ 0.34 | \$ 1.65 | \$ 1.27 |
| Diluted | \$ 1.07 | \$ 0.33 | \$ 1.58 | \$ 1.22 |
| Shares used in computing net income per share: | | | | |
| Basic | 32,234 | 33,389 | 32,552 | 32,935 |
| Diluted | 34,135 | 35,179 | 33,843 | 34,374 |

See notes to condensed consolidated financial statements (unaudited).

Table of Contents

SYNAPTICS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

| | Three Months Ended | | Nine Months Ended | |
|----------------------------------------------|---------------------------|-------------|--------------------------|-------------|
| | March 31, | | March 31, | |
| | 2013 | 2012 | 2013 | 2012 |
| Net income | \$ 36,446 | \$ 11,446 | \$ 53,613 | \$ 41,844 |
| Other comprehensive income, net of tax: | | | | |
| Change in unrealized net gain on investments | 842 | 1,820 | 2,680 | 13 |
| Comprehensive income | \$ 37,288 | \$ 13,266 | \$ 56,293 | \$ 41,857 |

See notes to condensed consolidated financial statements (unaudited).

Table of Contents**SYNAPTICS INCORPORATED AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands)

(unaudited)

| | Nine Months Ended March 31, | |
|-----------------------------------------------------------------------------------|----------------------------------------|-------------|
| | 2013 | 2012 |
| Cash flows from operating activities | | |
| Net income | \$ 53,613 | \$ 41,844 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Share-based compensation costs | 24,706 | 25,663 |
| Depreciation and amortization | 7,968 | 7,978 |
| Excess tax benefit from share-based compensation | (716) | (2,032) |
| Change in contingent consideration | 1,100 | |
| Deferred taxes | (2,373) | 40 |
| Impairment of property and equipment | 300 | 1,269 |
| Impairment recovery on investments, net | | (59) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, net | (2,560) | (1,685) |
| Inventories | (10,835) | 875 |
| Prepaid expenses and other current assets | 501 | (103) |
| Other assets | (2,964) | 1,325 |
| Accounts payable | 4,848 | 2,132 |
| Accrued compensation | 3,679 | (1,741) |
| Income taxes payable | (15,088) | (731) |
| Other accrued liabilities | 7,436 | 4,954 |
| Net cash provided by operating activities | 69,615 | 79,729 |
| Cash flows from investing activities | | |
| Proceeds from sales of non-current investments | 2,200 | 7,860 |
| Acquisition of business, net of cash acquired | (5,000) | |
| Purchases of property and equipment | (30,005) | (7,825) |
| Net cash (used in)/provided by investing activities | (32,805) | 35 |
| Cash flows from financing activities | | |
| Payment of contingent consideration | (4,600) | |
| Purchases of treasury stock | (31,280) | (33,524) |
| Proceeds from issuance of shares | 11,614 | 31,294 |
| Excess tax benefit from share-based compensation | 716 | 2,032 |
| Payroll taxes for deferred stock units | (2,752) | (2,601) |
| Net cash used in financing activities | (26,302) | (2,799) |
| Net increase in cash and cash equivalents | 10,508 | 76,965 |
| Cash and cash equivalents at beginning of period | 305,005 | 247,153 |
| Cash and cash equivalents at end of period | \$ 315,513 | \$ 324,118 |

Supplemental disclosures of cash flow information

| | | |
|----------------------------|-----------|-----------|
| Cash paid for income taxes | \$ 16,552 | \$ 11,787 |
|----------------------------|-----------|-----------|

See notes to condensed consolidated financial statements (unaudited).

Table of Contents

SYNAPTICS INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, and U.S. generally accepted accounting principles, or U.S. GAAP. However, certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such SEC rules and regulations. In our opinion, the financial statements include all adjustments, which are of a normal and recurring nature, necessary for the fair presentation of the results of the interim periods presented. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future period. These financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

The consolidated financial statements include our financial statements and those of our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.

Our fiscal year is the 52- or 53-week period ending on the last Saturday in June. Our fiscal 2013 is a 52-week period ending on June 29, 2013. Our fiscal 2012 was the 53-week period ended on June 30, 2012. The quarterly fiscal periods presented in this report were 13-week periods for the three months ended March 30, 2013 and March 31, 2012 and a 39-week period and 40-week period for the nine months ended March 30, 2013 and March 31, 2012, respectively. For ease of presentation, the accompanying consolidated financial statements have been shown as ending on calendar quarter end dates for all annual, interim, and quarterly financial statement captions, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, allowance for doubtful accounts, cost of revenue, inventories, loss on purchase commitments, product warranty, share-based compensation costs, provision for income taxes, deferred income tax asset valuation allowances, uncertain tax positions, tax contingencies, goodwill, intangible assets, investments, contingent consideration, and contingencies. We base our estimates on historical experience, applicable laws and regulations, and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Recently Issued Accounting Pronouncements

There are no new accounting pronouncements that are expected to have a material impact on our condensed consolidated financial statements.

2. Revenue Recognition

We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred and title has transferred, the price is fixed or determinable, and collection is reasonably assured, which is generally upon shipment. We accrue for estimated sales returns and other allowances, based on historical experience, at the time we recognize revenue.

Table of Contents**3. Net Income Per Share**

The computation of basic and diluted net income per share was as follows (in thousands, except per share data):

| | Three Months Ended March 31, | | Nine Months Ended March 31, | |
|---------------------------------------|---------------------------------|-----------|--------------------------------|-----------|
| | 2013 | 2012 | 2013 | 2012 |
| Numerator: | | | | |
| Net income | \$ 36,446 | \$ 11,446 | \$ 53,613 | \$ 41,844 |
| Denominator: | | | | |
| Shares, basic | 32,234 | 33,389 | 32,552 | 32,935 |
| Effect of dilutive share-based awards | 1,901 | 1,790 | 1,291 | 1,439 |
| Shares, diluted | 34,135 | 35,179 | 33,843 | 34,374 |
| Net income per share: | | | | |
| Basic | \$ 1.13 | \$ 0.34 | \$ 1.65 | \$ 1.27 |
| Diluted | \$ 1.07 | \$ 0.33 | \$ 1.58 | \$ 1.22 |

Our basic net income per share amounts for each period presented have been computed using the weighted average number of shares of common stock outstanding. Our diluted net income per share amounts for each period presented include the weighted average effect of potentially dilutive shares. We use the treasury stock method to determine the dilutive effect of our stock options, deferred stock units, or DSUs, market stock units, or MSUs, and convertible notes.

Dilutive net income per share amounts do not include the weighted average effect of 1,055,896 and 1,219,495 share-based awards that were outstanding during the three months ended March 31, 2013 and 2012, respectively, and 3,025,632 and 3,833,213 share-based awards that were outstanding during the nine months ended March 31, 2013 and 2012, respectively. These share-based awards were not included in the computation of diluted net income per share because their effect would have been antidilutive.

4. Fair Value

Financial assets and liabilities measured at fair value on a recurring basis, by level within the fair value hierarchy consisted of the following (in thousands):

| | March 31, 2013 | | June 30, 2012 | |
|----------------------------------------------------------------------|-------------------|-----------|------------------|-----------|
| | Level 1 | Level 3 | Level 1 | Level 3 |
| Assets | | | | |
| Money market | \$ 310,546 | \$ | \$ 301,451 | \$ |
| Auction rate securities | | 15,801 | | 15,321 |
| Total available-for-sale securities | \$ 310,546 | \$ 15,801 | \$ 301,451 | \$ 15,321 |
| Liabilities | | | | |
| Contingent consideration liability recorded for business combination | \$ | \$ 8,000 | \$ | \$ 11,900 |

In our condensed consolidated balance sheets as of March 31, 2013 and June 30, 2012, money market balances are included in cash and cash equivalents, auction rate securities, or ARS investments, are included in non-current investments, and contingent consideration liability recorded for business combination is included in other liabilities.

Table of Contents

Changes in fair value of our Level 3 financial assets as of March 31, 2013 were as follows (in thousands):

| | |
|------------------------------|-----------|
| Balance as of June 30, 2012 | \$ 15,321 |
| Net unrealized gain | 2,680 |
| Redemptions | (2,200) |
| Balance as of March 31, 2013 | \$ 15,801 |

Changes in fair value of contingent consideration measured using significant unobservable inputs (Level 3) as of March 31, 2013 were as follows (in thousands):

| | |
|-------------------------------------|-----------|
| Balance as of June 30, 2012 | \$ 11,900 |
| Payment of contingent consideration | (5,000) |
| Change in contingent consideration | 1,100 |
| Balance as of March 31, 2013 | \$ 8,000 |

In connection with the acquisition of Pacinian in June 2012, we entered into a contingent consideration arrangement, and subsequently paid \$5.0 million of additional consideration to the former Pacinian stockholders upon customer acceptance of a ThinTouch product. As of March 31, 2013, we owe up to \$10.0 million of additional consideration to the former Pacinian stockholders based on sales of products utilizing ThinTouch technology through June 2016. In our condensed consolidated statements of cash flows for the nine months ended March 31, 2013, \$4.6 million of the payment of contingent consideration was classified as cash flows from financing activities and \$400,000 was classified as cash flows from operating activities.

There were no transfers in or out of our Level 1 or 3 assets or liabilities during the nine months ended March 31, 2013.

The fair values of our cash equivalents, accounts receivable, and accounts payable approximate their carrying values because of the short-term nature of those instruments. The fair value of our notes payable approximates their carrying value.

5. Auction Rate Securities

Our ARS investments have failed to settle in auctions and are not liquid. In the event we need to access these funds prior to their maturity, we will not be able to do so without a loss of principal, unless redeemed by the issuers or a future auction on these investments is successful. During the three and nine months ended March 31, 2013, \$50,000 and \$2.2 million, respectively, of our ARS investments were redeemed at par.

As there are currently no active markets for our various failed ARS investments, we have estimated the fair value as of March 31, 2013 using a trinomial discounted cash flow analysis. The analysis considered, among others, the following factors:

the collateral underlying the security investments;

the creditworthiness of the counterparty;

the timing of expected future cash flows;

Edgar Filing: SYNAPTICS INC - Form 10-Q

the probability of a successful auction in a future period;

the underlying structure of each investment;

the present value of future principal and interest payments discounted at rates considered to reflect current market conditions;

a consideration of the probabilities of default, passing a future auction, or redemption at par for each period; and

estimates of the recovery rates in the event of default for each investment.

When possible, our failed ARS investments were compared to other observable market data or securities with similar characteristics. Our estimate of the fair value of our ARS investments could change materially from period to period based on future market conditions.

Table of Contents

Contractual maturities for our ARS investments are generally greater than five years, with fair value of \$11.5 million maturing from calendar years 2015 to 2017 and \$4.3 million maturing from calendar years 2041 to 2045. Of our ARS investments, \$6.7 million par value are investment grade, and the remaining \$18.5 million par value are below investment grade.

The various types of ARS investments we held as of March 31, 2013, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain/(loss), and fair value, consisted of the following (in thousands):

| | Original Cost Basis | Other-than- temporary Impairment in Retained Earnings | New Cost Basis | Unrealized Gain/(Loss) | Fair Value |
|---------------------|------------------------|----------------------------------------------------------------|-------------------|---------------------------|------------------|
| Student loans | \$ 4,650 | \$ (179) | \$ 4,471 | \$ (158) | \$ 4,313 |
| Credit linked notes | 13,500 | (8,765) | 4,735 | 4,850 | 9,585 |
| Preferred stock | 5,000 | (5,000) | | | |
| Municipals | 2,000 | (83) | 1,917 | (14) | 1,903 |
| Total ARS | \$ 25,150 | \$ (14,027) | \$ 11,123 | \$ 4,678 | \$ 15,801 |

The various types of ARS investments we held as of June 30, 2012, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain/(loss), and fair value, consisted of the following (in thousands):

| | Original Cost Basis | Other-than- temporary Impairment in Retained Earnings | New Cost Basis | Unrealized Gain/(Loss) | Fair Value |
|---------------------|------------------------|----------------------------------------------------------------|-------------------|---------------------------|------------------|
| Student loans | \$ 6,850 | \$ (179) | \$ 6,671 | \$ (231) | \$ 6,440 |
| Credit linked notes | 13,500 | (8,765) | 4,735 | 2,276 | 7,011 |
| Preferred stock | 5,000 | (5,000) | | | |
| Municipals | 2,000 | (83) | 1,917 | (47) | 1,870 |
| Total ARS | \$ 27,350 | \$ (14,027) | \$ 13,323 | \$ 1,998 | \$ 15,321 |

The ARS investments in each of the above tables with unrealized losses have been in a continuous unrealized loss position for more than 12 months.

We have accounted for all of our ARS investments as non-current as we are not able to reasonably determine when the ARS markets will recover or be restructured. Based on our ability to access our cash and cash equivalents, our expected operating cash flows, and our other sources of cash, we do not intend to sell the investments, and it is not more likely than not that we will be required to sell the investments before the recovery of the amortized cost basis. We will continue to monitor our ARS investments and evaluate our accounting for these investments quarterly.

6. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market (estimated net realizable value) and consisted of the following (in thousands):

| | March 31, 2013 | June 30, 2012 |
|----------------|-------------------|------------------|
| Raw materials | \$ 38,760 | \$ 26,957 |
| Finished goods | 5,151 | 4,710 |

| | |
|-----------|-----------|
| \$ 43,911 | \$ 31,667 |
|-----------|-----------|

Table of Contents**7. Other Accrued Liabilities**

Other accrued liabilities consisted of the following (in thousands):

| | March 31, 2013 | June 30, 2012 |
|-----------------------|-------------------|------------------|
| Customer obligations | \$ 17,621 | \$ 13,076 |
| Inventory obligations | 5,069 | 5,680 |
| Other | 11,675 | 7,759 |
| | \$ 34,365 | \$ 26,515 |

8. Product Warranties, Indemnifications, and Contingencies*Product Warranties*

We generally warrant our products for a period of 12 months from the date of sale and estimate probable product warranty costs at the time we recognize revenue. Factors that affect our warranty liability include historical and anticipated rates of warranty claims, materials usage, rework, and delivery costs. However, we assess the adequacy of our warranty obligations each reporting period and adjust the accrued warranty liability on the basis of our estimates.

Indemnifications

In connection with certain third-party agreements we have executed in the past, we are obligated to indemnify the third party in connection with any technology infringement by us. We have also entered into indemnification agreements with our officers and directors. Maximum potential future payments cannot be estimated because these agreements do not have a maximum stated liability. However, historical costs related to these indemnification provisions have not been significant. We have not recorded any liability in our consolidated financial statements for such indemnification obligations.

Contingencies

We have in the past and may in the future receive notices from third parties that claim our products infringe their intellectual property rights. We cannot be certain that our technologies and products do not or will not infringe issued patents or other proprietary rights of third parties.

Any infringement claims, with or without merit, could result in significant litigation costs and diversion of management and financial resources, including the payment of damages, which could have a material adverse effect on our business, financial condition, and results of operations.

9. Share-Based Compensation

Share-based compensation and the related tax benefit recognized in our condensed consolidated statements of income were as follows (in thousands):

| | Three Months Ended March 31, | | Nine Months Ended March 31, | |
|--------------------------------------|---------------------------------|----------|--------------------------------|-----------|
| | 2013 | 2012 | 2013 | 2012 |
| Cost of revenue | \$ 249 | \$ 313 | \$ 690 | \$ 903 |
| Research and development | 3,993 | 3,769 | 11,783 | 11,209 |
| Selling, general, and administrative | 3,991 | 4,915 | 12,233 | 13,551 |
| Total | \$ 8,233 | \$ 8,997 | \$ 24,706 | \$ 25,663 |

Edgar Filing: SYNAPTICS INC - Form 10-Q

| | | | | |
|------------------------------------------------|----------|----------|----------|----------|
| Income tax benefit on share-based compensation | \$ 2,279 | \$ 2,539 | \$ 6,676 | \$ 7,419 |
|------------------------------------------------|----------|----------|----------|----------|

Historically, we have issued new shares in connection with our share-based compensation plans; however, treasury shares were also available for issuance as of March 31, 2013, including shares repurchased under our common stock repurchase program.

Table of Contents*Stock Options*

Stock option activity, including stock options granted, exercised, and forfeited, and weighted average exercise prices for options outstanding and exercisable, and the aggregate intrinsic value were as follows:

| | Stock Option Awards Outstanding | Weighted Average Exercise Price | Aggregate Intrinsic Value (in thousands) |
|-------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------------|
| Balance at June 30, 2012 | 7,339,024 | \$ 25.34 | |
| Granted | 418,512 | 29.55 | |
| Exercised | (397,106) | 21.82 | |
| Forfeited | (397,025) | 29.50 | |
| Balance at March 31, 2013 | 6,963,405 | 25.56 | \$ 105,371 |
| Exercisable at March 31, 2013 | 5,267,249 | \$ 24.70 | \$ 84,205 |

The aggregate intrinsic value was determined using the closing price of our common stock on March 28, 2013 of \$40.69, and excludes the impact of stock options that were not in-the-money.

Deferred Stock Units

DSU activity, including DSUs granted, delivered, and forfeited, and the balance and aggregate intrinsic value of DSUs were as follows:

| | DSU Awards Outstanding | Aggregate Intrinsic Value (in thousands) |
|---------------------------|---------------------------|---------------------------------------------------|
| Balance at June 30, 2012 | 1,009,336 | |
| Granted | 479,384 | |
| Delivered | (320,631) | |
| Forfeited | (82,886) | |
| Balance at March 31, 2013 | 1,085,203 | \$ 44,157 |

The aggregate intrinsic value was determined using the closing price of our common stock on March 28, 2013 of \$40.69.

Of the shares delivered, 95,399 shares valued at \$2.8 million were withheld to meet statutory minimum tax withholding requirements.

Market Stock Units

Our Amended and Restated 2010 Incentive Compensation Plan provides for the grant of MSU awards, which are a type of DSU award, to our employees, consultants, and directors. An MSU is a promise to deliver shares of our common stock at a future date based on the achievement of market-based performance requirements in accordance with the terms of the MSU grant agreement. We began granting MSUs in November 2012.

In November 2012, we granted MSUs to our executive officers, which were designed to vest in three tranches with the target quantity for each tranche equal to one-third of the total MSU grant. The first tranche vests based on a one-year performance period; the second tranche vests based on a two-year performance period; and the third tranche vests based on a three-year performance period. Performance is measured on the achievement of a specified level of total stockholder return, or TSR, relative to the TSR of the Philadelphia Semiconductor Index, or SOX Index.

Edgar Filing: SYNAPTICS INC - Form 10-Q

The potential payout ranges from 0% to 200% of the grant target quantity and is adjusted on a two-to-one ratio based on our TSR performance relative to the SOX Index TSR performance using the following formula:

$$(100\% + ([\text{Synaptics TSR} - \text{SOX Index TSR}] \times 2))$$

Table of Contents

Delivery of shares earned, if any, will take place on the dates provided in the MSU grant agreement, assuming the grantee is still an employee, consultant, or director of our company at the end of the applicable performance period. On the delivery date, we withhold shares to cover statutory minimum tax withholding by delivering a net quantity of shares. Until delivery of shares, the grantee has no rights as a stockholder.

During the nine months ended March 31, 2013, we granted 74,000 MSUs and there were no shares under our MSU awards delivered or forfeited. We valued the MSUs using the Monte Carlo simulation model and amortize the compensation expense over the three-year performance and service period. The weighted average grant date fair value for the MSUs granted was \$25.82. The unrecognized share-based compensation cost for MSUs granted was approximately \$1.7 million as of March 31, 2013, which will be recognized over a weighted average period of approximately 1.5 years. As of March 31, 2013, the aggregate intrinsic value of the MSUs was \$3.0 million (assuming a 100% payout factor), which was determined using the closing price of our common stock on March 28, 2013 of \$40.69.

Employee Stock Purchase Plan

Shares purchased, weighted average purchase price, cash received, and the aggregate intrinsic value for employee stock purchase plan purchases during the nine-month period ended March 31, 2013 were as follows (in thousands, except for shares purchased and weighted average price):

| | |
|---------------------------------|----------|
| Shares purchased | 143,469 |
| Weighted average purchase price | \$ 20.56 |
| Cash received | \$ 2,950 |
| Aggregate intrinsic value | \$ 521 |

10. Income Taxes

We account for income taxes under the asset and liability method. We consider the operating earnings of our foreign subsidiaries to be indefinitely invested outside the United States. Accordingly, no provision has been made for the federal, state, or foreign taxes that may result from future remittances of undistributed earnings of our foreign subsidiaries.

The (benefit)/provision for income taxes of (\$12.6) million and \$3.6 million for the three months ended March 31, 2013 and 2012, respectively, represented estimated federal, foreign, and state income taxes. The effective tax rate for the three months ended March 31, 2013 was (52.8%) and diverged from the combined federal and state statutory rate primarily because of a net decrease in the liability for uncertain tax positions, which included the remeasurement of a prior year tax position, the retroactive reinstatement of the federal research credit, and foreign income taxed at lower tax rates, partially offset by foreign withholding taxes, and the tax impact of stock-based compensation associated with qualified stock options. The effective tax rate for the three months ended March 31, 2012 was 23.7% and diverged from the combined federal and state statutory rate primarily because of foreign income taxed at lower tax rates, and the federal and the state research credits, partially offset by foreign withholding taxes, the tax impact of stock-based compensation associated with qualified stock options, and an increase to the liability for uncertain tax position.

The (benefit)/provision for income taxes of (\$6.1) million and \$11.1 million for the nine months ended March 31, 2013 and 2012, respectively, represented estimated federal, foreign, and state income taxes. The effective tax rate for the nine months ended March 31, 2013 was (12.8%) and diverged from the combined federal and state statutory rate primarily because of a net decrease in the liability for uncertain tax positions, which included the remeasurement of a prior year tax position, the retroactive reinstatement of the federal research credit, and foreign income taxed at lower tax rates, partially offset by foreign withholding taxes and the tax impact of stock-based compensation associated with qualified stock options. The effective tax rate for the nine months ended March 31, 2012 was 21.0% and diverged from the combined federal and state statutory rate primarily because of foreign income taxed at lower tax rates and the federal and state research credits, partially offset by foreign withholding taxes and the tax impact of stock-based compensation associated with qualified stock options.

Unrecognized Tax Benefits

The total liability for gross unrecognized tax benefits decreased \$14.8 million during the nine months ended March 31, 2013 to \$8.3 million from \$23.1 million at June 30, 2012 and is included in other liabilities on our condensed consolidated balance sheets. The remaining liability for gross unrecognized tax benefits, if recognized, would reduce the effective tax rate on income from continuing operations. During the three months ended March 31, 2013, \$15.8 million of tax benefit was recognized in connection with the remeasurement of unrecognized tax benefits of a prior year tax position. The balance of interest and penalties accrued related to uncertain tax positions as of March 31, 2013 was \$917,000 and decreased by \$1.5 million from June 30, 2012. We classify interest and penalties as components of income tax expense.

Table of Contents

In May 2011, we were notified by the Internal Revenue Service (Service) that our fiscal 2003 through 2006 and fiscal 2008 through 2010 would be subject to examination. The early periods were being audited in connection with a mandatory review of tax refunds in excess of \$2.0 million when we carried back our fiscal 2008 net operating loss. In March 2013, we received the Revenue Agent's Report resolving our examination with the Service and paid an assessment that had no material impact to our condensed consolidated financial statements. Our case is pending review by the Joint Committee of Taxation, which we anticipate will extend into our fiscal 2014. Any prospective adjustments to our unrecognized tax benefits will be recorded as an increase or decrease to income tax expense and cause a corresponding change to our effective tax rate. Accordingly, our effective tax rate could fluctuate materially from period to period.

On January 2, 2013 President Barack Obama signed into law The American Taxpayer Relief Act of 2013 (The Act). The Act extends the federal research credit for two years retroactively from January 1, 2012 through December 31, 2013. As such, we recognized approximately a \$3.5 million tax benefit in the three months ended March 31, 2013, the period that includes the enactment date.

Our major tax jurisdictions are the United States and Hong Kong SAR, and fiscal 2003 onward remain subject to examination by one or more of these jurisdictions.

11. Segment, Customers, and Geographic Information

We operate in one segment: the development, marketing, and sale of interactive user interface solutions for electronic devices and products. We generate our revenue from two broad product categories: the mobile product market and the personal computing, or PC, market. The mobile product market accounted for 64% and 51% of net revenue for the three months ended March 31, 2013 and 2012, respectively, and 58% and 51% of net revenue for the nine months ended March 31, 2013 and 2012, respectively.

Net revenue within geographic areas based on our customers' locations for the periods presented was as follows (in thousands):

| | Three Months Ended March 31, | | Nine Months Ended March 31, | |
|--------|---------------------------------|------------|--------------------------------|------------|
| | 2013 | 2012 | 2013 | 2012 |
| China | \$ 96,897 | \$ 77,080 | \$ 277,192 | \$ 260,853 |
| Taiwan | 21,611 | 16,761 | 58,192 | 47,659 |
| Korea | 18,900 | 8,747 | 31,762 | 29,384 |
| Japan | 17,135 | 17,880 | 44,822 | 47,586 |
| Other | 8,781 | 11,237 | 21,437 | 25,139 |
| | \$ 163,324 | \$ 131,705 | \$ 433,405 | \$ 410,621 |

Net revenue from major customers as a percentage of total net revenue for the periods presented was as follows:

| | Three Months Ended March 31, | | Nine Months Ended March 31, | |
|------------|---------------------------------|------|--------------------------------|------|
| | 2013 | 2012 | 2013 | 2012 |
| Customer A | 12% | * | * | * |
| Customer B | * | 12% | * | 13% |

* Less than 10%

Table of Contents

We sell our products primarily to contract manufacturers that provide manufacturing services to original equipment manufacturers, or OEMs. We extend credit based on an evaluation of a customer's financial condition, and we generally do not require collateral. Major customer accounts receivable as a percentage of total accounts receivable at the dates presented were as follows:

| | March 31, 2013 | June 30, 2012 |
|------------|-------------------|------------------|
| Customer A | 12% | 14% |
| Customer B | 11% | 12% |

12. Comprehensive Income

Our comprehensive income generally consists of net income plus the effect of unrealized gains and losses on our investments, primarily due to temporary changes in market value of certain of our ARS investments. In addition, we recognize the noncredit portion of other-than-temporary impairment on debt securities in other comprehensive income. We recognize foreign currency remeasurement adjustments in our condensed consolidated statements of income as the U.S. dollar is the functional currency of our foreign entities.

13. Purchased Intangibles

The following table summarizes the life, the gross carrying value of our purchased intangible assets, and the related accumulated amortization as of March 31, 2013 and June 30, 2012 (in thousands):

| | Life | March 31, 2013 | June 30, 2012 |
|-------------------------------------|------------------|-------------------|------------------|
| In-process research and development | To be determined | \$ 8,900 | \$ 8,900 |
| Customer relationships | 5 years | 3,800 | 3,800 |
| Licensed technology and other | 5 years | 1,335 | |
| Patents | 5 years | 100 | 100 |
| | | 14,135 | 12,800 |
| Accumulated amortization | | (763) | |
| Purchased intangibles, net | | \$ 13,372 | \$ 12,800 |

Amortization of the purchased intangibles commenced in fiscal 2013. The total amortization expense for the purchased intangible assets was \$262,000 and \$763,000 for the three and nine months ended March 31, 2013, respectively. This amortization expense was included in our condensed consolidated statements of income as acquired intangibles amortization.

The following table presents expected annual aggregate amortization expense as of March 31, 2013 (in thousands):

| | |
|---------------------|-----------|
| Remainder of 2013 | \$ 262 |
| 2014 | 1,047 |
| 2015 | 1,047 |
| 2016 | 1,047 |
| 2017 | 1,047 |
| 2018 | 22 |
| To be determined | 8,900 |
| Future amortization | \$ 13,372 |

Table of Contents

14. Building and Land Sale and Corporate Headquarters Move

In October 2012, we entered into a purchase and sale agreement to sell our existing corporate headquarters, including an office building containing approximately 76,522 square feet of space located on approximately 2.59 acres of land. In January 2013, we entered into an amendment to the purchase and sale agreement to reduce the purchase price to approximately \$12.6 million, exclusive of adjustments and closing costs. The closing of the property sale transaction occurred in April 2013 and the resulting gain of approximately \$1.5 million will be included in our June quarter financial results. At the closing, we entered into a lease agreement with the buyer through May 31, 2013, unless we exercise our right to extend or terminate the lease prior to such date. The lease is at fair market value. As of March 31, 2013, we continue to utilize this building and therefore classify it as held for use.

We anticipate moving into our new company headquarters in June 2013. In connection with our move we will incur a one-time charge of up to \$600,000 on the abandonment of a leased building adjacent to the building we sold. The charge is expected to be included either in our June or September quarter financial results.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements and Factors That May Affect Results

You should read the following discussion and analysis in conjunction with our unaudited condensed consolidated financial statements and notes in Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

In addition to the historical information contained in this report, this report may contain forward-looking statements, including those related to our operating model and strategies; our market penetration and market share in the mobile product and PC markets; competitive factors in the mobile product and PC markets; revenue from the mobile product and PC markets; industry estimates of growth rates of these markets; average selling prices; product design mix; manufacturing costs; gross margins; new product solution introductions; customer relationships; research and development expenses; selling, general, and administrative expenses; liquidity and anticipated cash requirements; our ability to provide local sales, operational, and engineering support to customers; our assessment of the combination of the added value we bring to our OEM customers products in meeting their custom design requirements and the impact of our ongoing cost-improvement programs; our expectations regarding the timing of the conclusion of an ongoing appeal of a tax audit; and our expectations regarding tax benefits for the federal research credit. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.

We caution that these statements are qualified by various factors that may affect future results, including the following: economic conditions; changes in the market for our products and the success of our customers' products; our success in moving products from the design phase into the manufacturing phase; changes in the competitive environment; infringement claims; warranty obligations related to product failures; the failure of key technologies to deliver commercially acceptable performance; our dependence on certain key markets; penetration into new markets; the absence of both long-term purchase and supply commitments; and our lengthy development and product acceptance cycles. This report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2012, including particularly Item 1A Risk Factors therein.

Overview

We are a leading worldwide developer and supplier of custom-designed human interface solutions that enable people to interact more easily and intuitively with a wide variety of mobile computing, communications, entertainment, and other electronic devices. We believe our results to date reflect the combination of our customer focus, the strength of our intellectual property, and our engineering know-how, which allow us to develop or engineer products that meet the demanding design specifications of OEMs.

Many of our customers have manufacturing operations in China, and many of our OEM customers have established design centers in that region. With our expanded global presence, including offices in China, Finland, Hong Kong, Japan, Korea, Switzerland, Taiwan, and the United States, we are well positioned to provide local sales, operational, and engineering support services to our existing customers, as well as potential new customers, on a global basis.

Our manufacturing operations are based on a variable cost model in which we outsource all of our production requirements and generally drop ship our products directly to our customers from our contract manufacturers' facilities, reducing the need for significant capital expenditures and allowing us to minimize our investment in inventories. This approach requires us to work closely with our contract manufacturers and semiconductor foundries to ensure adequate production capacity to meet our forecasted volume requirements. We provide our contract manufacturers with six-month rolling forecasts and issue purchase orders based on our anticipated requirements for the next 90 days. However, we do not have any long-term supply contracts with any of our contract manufacturers. We use three third-party semiconductor foundries to supply wafers and two third-party packaging manufacturers to package our proprietary ASICs. In certain cases, we rely on a single source or a limited number of suppliers to provide other key components of our products. Our cost of revenue includes all costs associated with the production of our products, including materials, logistics, manufacturing, assembly, and test costs paid to third-party manufacturers and related overhead costs associated with our indirect manufacturing operations personnel. Additionally, we charge all warranty costs, yield losses, and any inventory provisions or write-downs to cost of revenue.

Table of Contents

Our gross margin generally reflects the combination of the added value we bring to our OEM customers' products in meeting their custom design requirements and the impact of our ongoing cost-improvement programs. These cost-improvement programs include reducing materials and component costs and implementing design and process improvements.

Our research and development expenses include costs for supplies and materials related to product development as well as the engineering costs incurred to design ASICs and human interface solutions for OEM customers prior to and after their commitment to incorporate those solutions into their products. These expenses have generally increased, reflecting our continuing commitment to the technological and design innovation required to maintain our position in our existing markets and to adapt our existing technologies or develop new technologies for new markets.

Selling, general, and administrative expenses include expenses related to sales, marketing, and administrative personnel; internal sales and outside sales representatives' commissions; market and usability research; outside legal, accounting, and consulting costs; and other marketing and sales activities. These expenses have generally increased, primarily reflecting incremental staffing and related support costs associated with our business acquisitions, increased business levels, growth in our existing markets, and penetration into new markets.

Critical Accounting Policies and Estimates

There have been no significant changes in our critical accounting policies and estimates during the nine months ended March 31, 2013 compared with our critical accounting policies and estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

Table of Contents**Results of Operations**

Certain of our condensed consolidated statements of income data for the periods indicated, together with comparative absolute and percentage changes in these amounts, were as follows (in thousands, except percentages):

| | Three Months Ended March 31, | | | | Nine Months Ended March 31, | | | |
|----------------------------------------------------|------------------------------|-----------|-----------|--------------------|-----------------------------|------------|-----------|--------------------|
| | 2013 | 2012 | \$ Change | % Change | 2013 | 2012 | \$ Change | % Change |
| Mobile product applications | \$ 104,673 | \$ 66,600 | \$ 38,073 | 57.2% | \$ 250,878 | \$ 209,618 | \$ 41,260 | 19.7% |
| PC product applications | 58,651 | 65,105 | (6,454) | (9.9%) | 182,527 | 201,003 | (18,476) | (9.2%) |
| Net revenue | 163,324 | 131,705 | 31,619 | 24.0% | 433,405 | 410,621 | 22,784 | 5.5% |
| Gross margin | 81,083 | 62,180 | 18,903 | 30.4% | 210,683 | 192,163 | 18,520 | 9.6% |
| Operating expenses: | | | | | | | | |
| Research and development | 36,740 | 29,415 | 7,325 | 24.9% | 103,799 | 87,478 | 16,321 | 18.7% |
| Selling, general, and administrative | 20,183 | 18,031 | 2,152 | 11.9% | 58,099 | 52,461 | 5,638 | 10.7% |
| Acquired intangibles amortization | 262 | | 262 | n/m ⁽¹⁾ | 763 | | 763 | n/m ⁽¹⁾ |
| Change in contingent consideration | 237 | | 237 | n/m ⁽¹⁾ | 1,100 | | 1,100 | n/m ⁽¹⁾ |
| Operating income | 23,661 | 14,734 | 8,927 | 60.6% | 46,922 | 52,224 | (5,302) | (10.2%) |
| Interest income | 197 | 231 | (34) | (14.7%) | 640 | 682 | (42) | (6.2%) |
| Interest expense | (4) | (4) | | 0.0% | (13) | (13) | | |
| Impairment recovery on investments, net | | 46 | (46) | (100.0%) | | 59 | (59) | (100.0%) |
| Income before (benefit)/provision for income taxes | 23,854 | 15,007 | 8,847 | 59.0% | 47,549 | 52,952 | (5,403) | (10.2%) |
| (Benefit)/provision for income taxes | (12,592) | 3,561 | (16,153) | (453.6%) | (6,064) | 11,108 | (17,172) | (154.6%) |
| Net income | \$ 36,446 | \$ 11,446 | \$ 25,000 | 218.4% | \$ 53,613 | \$ 41,844 | \$ 11,769 | 28.1% |

(1) not meaningful

Certain of our condensed consolidated statements of income data as a percentage of net revenue for the periods indicated were as follows:

| | Three Months Ended March 31, | | Point Increase/ (Decrease) | Nine Months Ended March 31, | | Point Increase/ (Decrease) |
|-----------------------------|------------------------------|--------|----------------------------|-----------------------------|--------|----------------------------|
| | 2013 | 2012 | | 2013 | 2012 | |
| Mobile product applications | 64.1% | 50.6% | 13.5% | 57.9% | 51.0% | 6.9% |
| PC product applications | 35.9% | 49.4% | (13.5%) | 42.1% | 49.0% | (6.9%) |
| Net revenue | 100.0% | 100.0% | | 100.0% | 100.0% | |
| Gross margin | 49.6% | 47.2% | 2.4% | 48.6% | 46.8% | 1.8% |

Edgar Filing: SYNAPTICS INC - Form 10-Q

| | | | | | | |
|----------------------------------------------------|--------|-------|--------------------|--------|-------|--------------------|
| Operating expenses: | | | | | | |
| Research and development | 22.5% | 22.3% | 0.2% | 23.9% | 21.3% | 2.6% |
| Selling, general, and administrative | 12.4% | 13.7% | (1.3%) | 13.4% | 12.8% | 0.6% |
| Amortization of acquired intangibles | 0.2% | | n/m ⁽¹⁾ | 0.2% | | n/m ⁽¹⁾ |
| Change in contingent consideration | 0.1% | | n/m ⁽¹⁾ | 0.3% | | n/m ⁽¹⁾ |
| Operating income | 14.5% | 11.2% | 3.3% | 10.8% | 12.7% | (1.9%) |
| Income before (benefit)/provision for income taxes | 14.6% | 11.4% | 3.2% | 11.0% | 12.9% | (1.9%) |
| (Benefit)/provision for income taxes | (7.7%) | 2.7% | (10.4%) | (1.4%) | 2.7% | (4.1%) |
| Net income | 22.3% | 8.7% | 13.6% | 12.4% | 10.2% | 2.2% |

(1) not meaningful
Net Revenue.

Net revenue was \$163.3 million for the quarter ended March 31, 2013 compared with \$131.7 million for the quarter ended March 31, 2012, an increase of \$31.6 million, or 24.0%. Of our third quarter fiscal 2013 net revenue, \$104.7 million, or 64.1%, was from mobile product applications and \$58.6 million, or 35.9%, was from PC product applications. The increase in net revenue for the quarter ended March 31, 2013 was attributable to an increase in net revenue from mobile product applications, partially offset by a decrease in PC product applications. Net revenue from mobile product applications increased primarily as a result of higher unit sales in the quarter, reflecting both the growing market and our market share. Net revenue from PC product applications decreased primarily as a result of lower unit sales in the quarter, reflecting the continued weakness in the PC market.

Table of Contents

Net revenue was \$433.4 million for the nine months ended March 31, 2013 compared with \$410.6 million for the nine months ended March 31, 2012, an increase of \$22.8 million, or 5.5%. Of our first nine months of fiscal 2013 net revenue, \$250.9 million, or 57.9%, was from mobile product applications and \$182.5 million, or 42.1%, was from PC product applications. The increase in net revenue for the nine months ended March 31, 2013 was attributable to an increase in mobile product applications, partially offset by a decrease in net revenue from PC product applications. Net revenue from mobile product applications increased primarily as a result of higher unit sales in the first nine months of the fiscal year, reflecting the growing market. Net revenue from PC product applications decreased primarily as a result of lower unit sales in the first nine months of the fiscal year, reflecting the continued weakness in the PC market.

Based on industry estimates of unit shipments, the notebook market is anticipated to increase less than 1%, and the mobile smartphone market is anticipated to increase approximately 28% in calendar year 2013 compared with calendar year 2012.

Gross Margin.

Gross margin as a percentage of net revenue was 49.6%, or \$81.1 million, for the quarter ended March 31, 2013 compared with 47.2%, or \$62.2 million, for the quarter ended March 31, 2012. The 240 basis point improvement in gross margin was primarily attributable to favorable mix of higher margin mobile product application revenue driven largely by the continued shift in our overall revenue mix to mobile product revenue consisting predominately of higher margin chip solutions.

Gross margin as a percentage of net revenue was 48.6%, or \$210.7 million, for the nine months ended March 31, 2013 compared with 46.8%, or \$192.2 million, for the nine months ended March 31, 2012. The 180 basis point improvement in gross margin was primarily attributable to favorable mix of higher margin mobile product application revenue driven largely by the continued shift in our overall revenue mix to mobile product revenue consisting predominately of higher margin chip solutions.

We continuously introduce new product solutions, many of which have life cycles of less than a year. Further, as we sell our capacitive sensing technology in designs that are generally unique or specific to an OEM customer's application, gross margin varies on a product-by-product basis, making our cumulative gross margin a blend of our product specific designs. As a virtual manufacturer, our gross margin percentage is generally not impacted materially by our shipment volume. We charge losses on inventory purchase obligations and write-downs to reduce the carrying value of obsolete, slow moving, and non-usable inventory to net realizable value (including warranty costs), to cost of revenue.

Operating Expenses.

Research and Development Expenses. Research and development expenses increased \$7.3 million to \$36.7 million for the quarter ended March 31, 2013 compared with the quarter ended March 31, 2012. The increase in research and development expenses primarily reflected a \$4.9 million increase in employee-related costs, which included our annual merit increase, an increase in our incentive compensation accrual, additional headcount associated with our recent acquisitions and planned headcount expansion, and a \$1.7 million increase in infrastructure-related costs.

Research and development expenses increased \$16.3 million to \$103.8 million for the nine months ended March 31, 2013 compared with the nine months ended March 31, 2012. The increase in research and development expenses primarily reflected a \$10.6 million increase in employee-related costs, which included our annual merit increase, an increase in our incentive compensation accrual, additional headcount associated with our recent acquisitions and planned headcount expansion, a \$3.0 million increase in infrastructure-related costs, and a \$1.9 million increase in temporary employee expenses.

Selling, General, and Administrative Expenses. Selling, general, and administrative expenses increased \$2.2 million to \$20.2 million for the quarter ended March 31, 2013 compared with the quarter ended March 31, 2012. The increase in selling, general, and administrative expenses primarily reflected a \$1.7 million increase in employee-related costs, which included our annual merit increase, an increase in our incentive compensation accrual and additional headcount associated with our recent acquisitions, and a \$271,000 increase in travel related costs.

Table of Contents

Selling, general, and administrative expenses increased \$5.6 million to \$58.1 million for the nine months ended March 31, 2013 compared with the nine months ended March 31, 2012. The increase in selling, general, and administrative expenses primarily reflected a \$3.0 million increase in employee-related costs, which included our annual merit increase, an increase in our incentive compensation accrual, additional headcount associated with our recent acquisitions, a \$1.2 million increase in support costs, an \$827,000 increase in professional fees, and a \$381,000 increase in travel related costs.

Provision for Income Taxes.

We account for income taxes under the asset and liability method. We consider the operating earnings of our foreign subsidiaries to be indefinitely invested outside the United States. Accordingly, no provision has been made for the federal, state, or foreign taxes that may result from future repatriation of undistributed earnings of our foreign subsidiaries.

The (benefit)/provision for income taxes of (\$12.6) million and \$3.6 million for the three months ended March 31, 2013 and 2012, respectively, represented estimated federal, foreign, and state income taxes. The effective tax rate for the three months ended March 31, 2013 was (52.8%) and diverged from the combined federal and state statutory rate primarily because of a net decrease in the liability for uncertain tax positions, which included the remeasurement of a prior year tax position, the retroactive reinstatement of the federal research credit, and foreign income taxed at lower tax rates, partially offset by foreign withholding taxes, and the tax impact of stock-based compensation associated with qualified stock options. The effective tax rate for the three months ended March 31, 2012 was 23.7% and diverged from the combined federal and state statutory rate primarily because of foreign income taxed at lower tax rates, and the federal and the state research credits, partially offset by foreign withholding taxes, the tax impact of stock-based compensation associated with qualified stock options, and an increase to the liability for uncertain tax position.

The (benefit)/provision for income taxes of (\$6.1) million and \$11.1 million for the nine months ended March 31, 2013 and 2012, respectively, represented estimated federal, foreign, and state income taxes. The effective tax rate for the nine months ended March 31, 2013 was (12.8%) and diverged from the combined federal and state statutory rate primarily because of a net decrease in the liability for uncertain tax positions, which included the remeasurement of a prior year tax position, the retroactive reinstatement of the federal research credit, and foreign income taxed at lower tax rates, partially offset by foreign withholding taxes and the tax impact of stock-based compensation associated with qualified stock options. The effective tax rate for the nine months ended March 31, 2012 was 21.0% and diverged from the combined federal and state statutory rate primarily because of foreign income taxed at lower tax rates and the federal and state research credits, partially offset by foreign withholding taxes and the tax impact of stock-based compensation associated with qualified stock options.

In May 2011, we were notified by the Internal Revenue Service (Service) that our fiscal 2003 through 2006 and fiscal 2008 through 2010 would be subject to an audit. The early periods were being audited in connection with a mandatory review of tax refunds in excess of \$2.0 million when we carried back our fiscal 2008 net operating loss. In March 2013, we received the Revenue Agent's report resolving our examination with the Service and paid an assessment that had no material impact to our condensed consolidated financial statements which triggered the reevaluation of the measurement of prior year uncertain tax positions and resulted in the recognition of \$15.8 million of previously unrecognized tax benefits in the March quarter. Our case is pending review by the Joint Committee of Taxation, which we anticipate will extend into our fiscal 2014. Any prospective adjustments to our unrecognized tax benefits will be recorded as an increase or decrease to income tax expense and cause a corresponding change to our effective tax rate. Accordingly, our effective tax rate could fluctuate materially from period to period.

On January 2, 2013 President Barack Obama signed into law The American Taxpayer Relief Act of 2013 (The Act). The Act extends the federal research credit for two years retroactively from January 1, 2012 through December 31, 2013. As such, we recognized approximately a \$3.5 million tax benefit in the three months ended March 31, 2013, the financial period that includes the enactment date.

Liquidity and Capital Resources

Our cash and cash equivalents were \$315.5 million as of March 31, 2013 compared with \$305.0 million as of June 30, 2012, an increase of \$10.5 million. The increase primarily reflects the combination of \$69.6 million provided from operating cash flows, \$11.6 million of proceeds from the issuance of shares and \$2.2 million of proceeds from the sales and maturities of non-current investments, offset by \$30.0 million used for the purchase of property and equipment, \$5.0 million used for the acquisition of a business, \$4.6 million used for the payment of contingent consideration, and \$31.3 million used to repurchase 1,240,440 shares of our common stock. We consider earnings of our foreign subsidiaries indefinitely invested overseas and have made no provision for income or withholding taxes that may result from a future repatriation of those earnings. As of March 31, 2013, \$278.0 million of cash and cash equivalents was held by our foreign subsidiaries. If these funds are needed for our operations in the United States, we would be required to accrue and pay U.S. federal, foreign, and state taxes to repatriate these funds.

Table of Contents

Cash Flows from Operating Activities. Operating activities during the nine months ended March 31, 2013 generated net cash of \$69.6 million compared with \$79.7 million of net cash generated during the nine months ended March 31, 2012. For the nine months ended March 31, 2013, net cash provided by operating activities was primarily attributable to net income of \$53.6 million plus adjustments for non-cash charges of \$31.0 million, and a \$15.0 million net change in operating assets and liabilities. The net change in operating assets and liabilities was primarily attributable to a \$15.1 million decrease in income taxes payable, a \$10.8 million increase in inventories, partially offset by a \$7.4 million increase in other accrued liabilities, a \$4.8 million increase in accounts payable, and a \$3.7 million increase in accrued compensation. From June 30, 2012 to March 31, 2013, our days sales outstanding decreased from 68 to 59 days and our inventory turns declined from 9 to 7.

Cash Flows from Investing Activities. Our investing activities primarily relate to purchases of property and equipment and business purchases. Investing activities during the nine months ended March 31, 2013 used net cash of \$32.8 million compared with \$35,000 net cash provided by investing activities during the nine months ended March 31, 2012. During the nine months ended March 31, 2013, net cash used in investing activities consisted of \$30.0 million used for the purchase of property and equipment (which included \$11.9 million for the purchase of buildings and land) and \$5.0 million used for the acquisition of a business, partially offset by proceeds of \$2.2 million from the sale and redemption of non-current investments.

Cash Flows from Financing Activities. Net cash used in financing activities for the nine months ended March 31, 2013 was \$26.3 million compared with \$2.8 million for the nine months ended March 31, 2012. Net cash used in financing activities for the nine months ended March 31, 2013 included \$31.3 million used to repurchase 1,240,440 shares of our common stock as well as \$4.6 million used for the portion of the payment of contingent consideration identified as a financing activity, partially offset by proceeds from issuance of shares of our common stock of \$11.6 million.

Common Stock Repurchase Program. Our Board of Directors has cumulatively authorized \$520.0 million for our stock repurchase program, expiring in October 2013. The program authorizes us to purchase our common stock in the open market or in privately negotiated transactions, depending upon market conditions and other factors. The number of shares purchased and the timing of purchases is based on the level of our cash balances, general business and market conditions, and other factors, including alternative investment opportunities. Common stock purchased under this program is held as treasury stock. From April 2005 through March 31, 2013, we purchased 17,024,532 shares of our common stock in the open market for an aggregate cost of \$445.2 million. Treasury shares purchased prior to August 28, 2008 were not subject to the stock split on that date. As of March 31, 2013, we had \$74.8 million remaining under our common stock repurchase program.

Bank Credit Facility. We maintain a \$50.0 million working capital line of credit with Wells Fargo Bank. The Wells Fargo Bank revolving line of credit, which expires on September 1, 2013, provides for an interest rate equal to the prime lending rate or 250 basis points above LIBOR, depending on whether we choose a variable or fixed rate, respectively. We had not borrowed any amounts under the line of credit as of March 31, 2013.

\$100 Million Shelf Registration. We have registered an aggregate of \$100.0 million of common stock and preferred stock for issuance in connection with acquisitions, which shares generally will be freely tradable after their issuance under Rule 145 of the Securities Act unless held by an affiliate of the acquired company, in which case such shares will be subject to the volume and manner of sale restrictions of Rule 144.

Liquidity and Capital Resources. We believe our existing cash and cash equivalents and anticipated cash flows from operating activities will be sufficient to meet our working capital and other cash requirements for at least the next 12 months. Our future capital requirements will depend on many factors, including our revenue, the timing and extent of spending to support product development efforts, costs related to protecting our intellectual property, the expansion of sales and marketing activities, the timing of introductions of new products and enhancements to existing products, the costs to ensure access to adequate manufacturing capacity, the costs of maintaining sufficient space or renovating recently acquired building space for our expanding workforce, the continuing market acceptance of our product solutions, our common stock repurchase program, and the amount and timing of our investments in, or acquisitions of, other technologies or companies. Further equity or debt financing may not be available to us on acceptable terms or at all. If sufficient funds are not available or are not available on acceptable terms, our ability to take advantage of business opportunities or to respond to competitive pressures could be limited or severely constrained.

Table of Contents

Our non-current investments consist of ARS investments, which have failed to settle in auctions. These investments are not liquid, and in the event we need to access these funds, we will not be able to do so without a loss of principal, unless redeemed by the issuers or a future auction on these investments is successful.

Based on our ability to access our cash and cash equivalents, our expected operating cash flows, and our other sources of cash, we do not anticipate the lack of liquidity on these investments will affect our ability to operate our business as usual. Further, we do not anticipate the need to repatriate any undistributed earnings of our foreign subsidiaries to meet our working capital and other cash requirements.

Contractual Obligations and Commercial Commitments

Our material contractual obligations and commercial commitments as of March 31, 2013 were as follows (in millions):

| | Remaining in Fiscal Year 2013 | Fiscal Year 2014 | Payments due by period | | | | Thereafter | Total |
|------------------------------------------------|-------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------|-------|
| | | | Fiscal Year 2015 | Fiscal Year 2016 | Fiscal Year 2017 | Fiscal Year 2018 | | |
| | | | | | | | | |
| Convertible senior subordinated notes (1) | \$ | \$ | \$ | \$ | \$ | \$ | \$ 3 | \$ 3 |
| Leases | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 9 |
| Purchase obligations and other commitments (2) | 14 | 1 | | | | | | 15 |
| Total | \$ 15 | \$ 4 | \$ 1 | \$ 1 | \$ 1 | \$ 1 | \$ 4 | \$ 27 |

- (1) Represents both principal and interest payable through the maturity date of the underlying contractual obligations.
(2) Purchase obligations and other commitments include payments due under a building construction agreement, a long-term services agreement and inventory purchase obligations with contract manufacturers.

In connection with the acquisition of Pacinian in June 2012, we entered into a contingent consideration arrangement. As of March 31, 2013, we owe up to \$10.0 million of additional consideration to the former Pacinian stockholders based on sales of products utilizing ThinTouch technology through June 2016. The estimated fair value of the contingent consideration liability as of March 31, 2013 was \$8.0 million. This obligation is excluded from the table above due to the difficulty in making reasonably reliable estimates of the timing of the cash payments.

The amounts in the table above exclude unrecognized tax benefits of \$8.3 million. As of March 31, 2013, we were unable to make a reasonably reliable estimate of when cash settlement with a taxing authority may occur in connection with our gross unrecognized tax benefit.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risk has not changed materially from the interest rate and foreign currency exchange risks disclosed in Item 7A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, which included inquiries made to certain other of our employees. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have each concluded that our disclosure controls and procedures are designed and are effective to ensure that information required to be disclosed is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective and sufficient to ensure that we record, process, summarize, and report information required to be disclosed by us in our periodic reports filed under the Securities Exchange Act of 1934, as amended, within the time periods specified by the SEC's rules and forms.

Edgar Filing: SYNAPTICS INC - Form 10-Q

During the fiscal quarter covered by this report, there have not been any changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

Our cumulative authorization for our common stock repurchase program is \$520.0 million. The remaining amount authorized for the repurchase of our common stock through October 2013 is \$74.8 million. There were no repurchases under our common stock repurchase program during the three-month period ended March 31, 2013.

Table of Contents

ITEM 6. EXHIBITS

| | |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.33(b) | Second Amendment to Agreement of Purchase and Sale and Escrow Instructions dated as of January 4, 2013 between Orchard Partners, LLC and the registrant |
| 31.1 | Certification of Chief Executive Officer |
| 31.2 | Certification of Chief Financial Officer |
| 32.1 | Section 1350 Certification of Chief Executive Officer |
| 32.2 | Section 1350 Certification of Chief Financial Officer |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYNAPTICS INCORPORATED

Date: May 3, 2013

By: /s/ Richard A. Bergman
Name: Richard A. Bergman
Title: President and Chief Executive Officer

Date: May 3, 2013

By: /s/ Kathleen A. Bayless
Name: Kathleen A. Bayless
Title: Senior Vice President, Chief Financial Officer, Secretary, and Treasurer

Table of Contents

INDEX TO EXHIBITS

| Exhibit Number | Exhibit |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.33(b) | Second Amendment to Agreement of Purchase and Sale and Escrow Instructions dated as of January 4, 2013 between Orchard Partners, LLC and the registrant |
| 31.1 | Certification of Chief Executive Officer |
| 31.2 | Certification of Chief Financial Officer |
| 32.1 | Section 1350 Certification of Chief Executive Officer |
| 32.2 | Section 1350 Certification of Chief Financial Officer |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |